(Q40539148)

21 September 2017

1 reference

title

Immunotherapy for renal cell carcinoma: the era of interleukin-2-based treatment (English)

1 reference

21 September 2017

1 reference

Taneja SS

1

1 reference

21 September 2017

Pierce W

series ordinal

2

1 reference

21 September 2017

Figlin R

series ordinal

3

1 reference

21 September 2017

Belldegrun A

series ordinal

4

1 reference

21 September 2017

language of work or name

English

0 references

publication date

1 June 1995

1 reference

21 September 2017

1 reference

21 September 2017

45

1 reference

21 September 2017

911-924

1 reference

21 September 2017

6

1 reference

Of historical interest. General Grant fights cancer

21 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

Aggressive treatment of metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

Prognostic factors in metastatic renal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

Validation of the tumor, nodes and metastasis classification of renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

Radical extensive surgery for renal cell carcinoma: long-term results and prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

Selective in Vitro Growth of T Lymphocytes from Normal Human Bone Marrows

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

Structure and expression of a cloned cDNA for human interleukin-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

Biological Activity of Recombinant Human Interleukin-2 Produced inEscherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

Lymphokine-activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

Anti-tumor reactivity of human lymphokine activated killer (LAK) cells against fresh and cultured preparations of renal cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

Patterns of cytokine release of unselected and CD8+ selected renal cell carcinoma tumor-infiltrating lymphocytes (TIL). Evidence for enhanced specific killing of tumor necrosis factor-secreting/IL-6 nonsecreting TIL in vitro and correlation with com

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant interleukin-2 in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

Cardiorespiratory effects of immunotherapy with interleukin-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

Myocardial toxic effects during recombinant interleukin-2 therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

Toxicity of immunotherapy with interleukin-2 and lymphokine-activated killer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

Interleukin-2 toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

NIH conference. New approaches to the immunotherapy of cancer using interleukin-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

High-dose recombinant interleukin-2 alone: a regimen with limited activity in the treatment of advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

Recombinant interleukin-2 in metastatic renal cell carcinoma—A European multicentre phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

Treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2: a single-center phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

Phase II trial of high-dose intermittent interleukin-2 in metastatic renal cell carcinoma: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

Antitumor effects of interleukin 2 against renal cell carcinoma: basic study and clinical application

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

Interleukin-2 by Inhalation: Local Therapy for Metastatic Renal Cell Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

The treatment of renal cell carcinoma with human leukocyte alpha-interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

Recombinant interferon alfa-2a in metastatic renal cell carcinoma: assessment of antitumor activity and anti-interferon antibody formation

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

Phase II study of alpha interferon on renal cell carcinoma. Summary of three collaborative trials

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

The natural history of metastatic renal cell carcinoma: a computer analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

Interferon in renal cell carcinoma. The UCLA experience.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

In vivo anti-tumor activity of combinations of interferon alpha and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

A phase II trial of interleukin-2 by continuous infusion and interferon by intramuscular injection in patients with renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

A phase I study of subcutaneous recombinant interleukin-2 and interferon alfa-2a

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

Phase II study of interferon-alpha and chemotherapy (5-fluorouracil and mitomycin C) in metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

Cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

Solitary Metastasis from Renal Cell Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

Surgery following response to interferon-alpha-based therapy for residual renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

Study of Tumor-Infiltrating Lymphocytes for Adoptive Therapy of Renal Cell Carcinoma (RCC) and Metastatic Melanoma: Sequential Proliferation of Cytotoxic Natural Killer and Noncytotoxic T Cells in RCC

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

Inpatient continuous-infusion interleukin-2 in 788 patients with cancer. The National Biotherapy Study Group experience.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980108-3

7 January 2021

10.1016/S0090-4295(99)80108-3

Identifiers

DOI

1 reference

21 September 2017

1 reference